T-cell receptor Vβ repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation

Scandinavian Journal of Immunology

Volumn 61, Issue 3, 2005, Pages 285-294

  Hentschke, P ^a   Omazic, B ^b   Mattsson, J ^a   Nasman Bjork I ^c   Lundkvist, I ^b   Gigliotti, D ^a   Barkholt, L ^a   Ringden O ^a   Remberger, M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Arvid Wretlind Laboratory   (Sweden)

^c BIOVITRUM AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CD4 ANTIGEN; CD8 ANTIGEN; COMPLEMENTARY DNA; CONCANAVALIN A; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE PHOSPHATE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MITOGENIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHYTOHEMAGGLUTININ; T LYMPHOCYTE RECEPTOR BETA CHAIN; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTIGENS; BASE SEQUENCE; CHIMERA; COMPLEMENTARITY DETERMINING REGIONS; DNA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MITOGENS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 16244382862     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01564.x     Document Type: Article

References (33)

1. Storb R, Thomas ED. Allogeneic bone-marrow transplantation. Immunol Rev 1983;71:77-102.
2. Storek J, Wells D, Dawson MA, Storer B, Maloney DG. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 2001;98:489-91.
3. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E. Analysis of T-cell repopulation after allogeneic bone marrow transplantation: significant differences between recipients of T-cell depleted and unmanipulated grafts. Blood 1996;87:3984-92.
4. Hedrick SM, Engel I, McElligott DL et al. Selection of amino acid sequences in the beta chain of the T cell antigen receptor. Science 1988;239:1541-4.
5. Garcia KC, Degano M, Pease LR et al. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science 1998;279:1166-72.
6. Wu CJ, Chillemi A, Alyea EP et al. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism, Blood 2000;95:352-9.
7. Gorski J, Yassai M, Zhu X et al. Circulating T cell repertoire complexity in normal individuals and bone marrow recipients analyzed by CDR3 size spectratyping. Correlation with immune status. J Immunol 1994;152:5109-19.
8. Akatsuka Y, Cerveny C, Hansen JA. T cell receptor clonal diversity following allogeneic marrow grafting. Hum Immunol 1996;48:125-34.
9. Storek J, Joseph A, Dawson MA, Douek DC, Storer B, Maloney DG. Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation. Transplantation 2002;73:1154-8.
10. Verfuerth S, Peggs K, Vyas P, Barnett L, O'Reilly RJ, Mackinnon S. Longitudinal monitoring of immune reconstitution by CDR3 size spectratyping after T-cell-depleted allogeneic bone marrow transplant and the effect of donor lymphocyte infusions on T-cell repertoire. Blood 2000;95:3990-5.
11. Ringden O, Pihlstedt P, Markling L et al. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 1991;7:221-6.
12. Ringden O, Remberger M, Persson U et al. Similar incidence of graft-vetsus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-25.
13. Hentschke P, Barkholt L, Uzunel M et al. Low-intensity conditioning and hematopoiecic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003;31:253-61.
14. Wahlstrom J, Gigliotti D, Roquet A, Wigzell H, Eklund A, Grunewald J. T cell receptor Vbeta expression in patients with allergic asthma befote and aftet repeated low-dose allergen inhalation. Clin Immunol 2001;100:31-9.
15. Gokmen E, Bachier C, Raaphorst FM et al. Ex vivo-expanded hematopoietic cell graft recipients exhibit T cell repertoire diversity similar to that seen after conventional stem cell transplants. J Hematother Stem Cell Res 2001;10:53-66.
16. Mattsson J, Uzunel M, Remberger M, Ringden O. T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation. Transplantation 2001;71:433-9.
17. Epperson DE, Margolis DA, McOlash L, Janczak T, Barren AJ. In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation. Br J Haematol 2001;114:57-62.
18. Stoiser B, Knobl P, Fonatsch C et al. Prognosis of patients with a second relapse of acute myeloid leukemia. Leukemia 2000;14:2059-63.
19. Mauch P, Constine L, Greenberger J et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1319-39.
20. Morecki S, Gelfand Y, Nagler A et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001;28:243-9.
21. Gratama JW, Bolhuis RL. Monitoring of T-lymphocyte regeneration following allogeneic bone marrow transplantation using monoclonal antibodies. Neth J Med 1985;28:128-33.
22. Maini MK, Casorati G, Dellabona P, Wack A, Beverley PC. T-cell clonality in immune responses. Immunol Today 1999;20:262.
23. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986;153:478-88.
24. Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood 2003;102:4255-60.
25. Paulin T, Ringden O, Lonnqvist B. Faster immunological recovery after bone marrow transplantation in patients without cytomegalovirus infection. Transplantation 1985;39:377-84.
26. Uzunel M, Mattsson J, Brune M, Johansson JE, Aschan J, Ringden O. Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 2003;101:469-72.
27. Weaver CH, Longin K, Buckner CD, Bensinger W. Lymphocyte content in peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994;13:411-5.
28. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996;88:2775-9.
29. Storek J, Witherspoon RP, Maloney DG, Chauncey TR, Storb R. Improved reconstitution of CD4 T cells and B cells but worsened reconstitution of serum IgG levels after allogeneic transplantation of blood stem cells instead of marrow. Blood 1997;89:3891-3.
30. Friedman TM, Varadi G, Hopely DD et al. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches. Biol Blood Marrow Transplant 2001;7:656-64.
31. Junghanss C, Marr KA. Carter RA et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002;8:512-20.
32. Mohty M, Faucher C, Vey N et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000;26:251-5.
33. Nakai K, Kanda Y, Mineishi S et al. Suspected delayed immune recovery against cytomegalovirus after reduced-intensity stem cell transplantation using anti-thymocyte globulin. Bone Marrow Transplant 2002;29:237-41.